| Date | Title | Description |
| 19.03.2026 | Swiss biotechs advance clinical programs across multiple therapeutic areas |
Pilatus Biosciences, a startup based in Vaud, is developing novel immunotherapies for liver and gastrointestinal cancers. Founded in 2022 from the Ludwig Institute for Cancer Research and supported by the Cancer Research Institute, Pilatus... |
| 13.03.2026 | Swiss startups bring in new leadership across health tech, AI and clean mobility |
Docjo, founded in 2023, has developed a platform for continuous digital communication between patients and healthcare professionals, with a focus on chronic disease management. The company has appointed Roger Pierenkemper as CEO, succeedin... |
| 15.01.2026 | Santhera obtains regulatory approval in Switzerland |
The Swissmedic has approved AGAMREE in Switzerland based on the data from the pivotal Phase 2b VISION-DMD study and assessment results from the European Medicines Agency. In the pivotal VISION-DMD study, AGAMREE met the primary endpoint Ti... |
| 07.11.2025 | Development milestones and financing for biotech companies |
Timeline, a longevity biotech company behind Mitopure® (Urolithin A) — a postbiotic that stimulates mitophagy, the body’s cellular recycling process critical for mitochondrial and metabolic health — has published a new clinical study on im... |
| 24.09.2025 | Business and clinical advancements propel Swiss biotech companies |
Topadur is currently conducting a Phase 2a clinical trial evaluating TOP-N53 in patients with systemic sclerosis-related digital ulcers, a rare, life-threatening autoimmune disease characterized by fibrosis, vascular damage, and chronic di... |
| 21.07.2025 | Drei Startups verstärken ihre Verwaltungsräte |
Das Zürcher Food-Startup kaisin. kann neu auf das Wissen, die Erfahrungen und Kompetenzen von Bettina Heinzmann im Verwaltungsrat zählen. Heinzmann, Mitgründerin des Women in Retail Switzerland + Friends Netzwerks, bringe breites Fachwisse... |
| 20.05.2025 | Santheras Aktionäre stimmen an der heutigen Generalversammlung allen Anträgen des Verwaltungsrats zu | Pratteln, Schweiz, 20. Mai 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt heute bekannt, dass die Aktionäre an der heutigen Generalversammlung (GV) in Pratteln, Schweiz, allen Anträgen des Verwaltungsrates mit grosser Mehrheit zugestimmt ... |
| 29.04.2025 | Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung | Pratteln, Schweiz, 29. April 2025 - Santhera Pharmaceuticals (SIX: SANN) hat heute die Einladung zur ordentlichen Generalversammlung (GV) veröffentlicht, die am 20. Mai 2025 um 10:00 Uhr MESZ im Haus der Wirtschaft, Hardstrasse 1, 4133 Prat... |
| 29.04.2025 | Gesamtjahresergebnisse für das am 31. Dezember 2024 endende Jahr | Ein Jahr des Wandels nach der erfolgreichen Einführung von AGAMREE®
Pratteln, Schweiz, 29. April 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt heute die Ergebnisse für das am 31. Dezember 2024 abgeschlossene Geschäftsjahr bekannt.
Dario ... |
| 29.04.2025 | Santhera Publishes Agenda for its Annual General Meeting | Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 20, 2025, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 P... |
| 23.04.2025 | A New Dawn in Cancer Treatment: Onward Therapeutics' Bold Move with NK Cell Therapy | In the world of biotechnology, breakthroughs often feel like whispers in a storm. Yet, some announcements resonate like thunder. Onward Therapeutics has just made such a declaration. The company, rooted in Switzerland, is stepping into the ... |
| 23.04.2025 | Swiss biotechs on track to address key medical challenges |
Onward Therapeutics SA is focused on advancing innovative cancer immunotherapies through a fast-track development model. Its portfolio includes a bispecific antibody (OT-A201) licensed from Biomunex, alongside an equity investment; and an ... |
| 16.04.2025 | Santhera informiert über den kommerziellen Rollout von AGAMREE® | Pratteln, Schweiz, 16. April 2025 - Santhera Pharmaceuticals (SIX: SANN) gibt den neuesten Fortschritt beim kommerziellen Rollout von AGAMREE® zur Behandlung von Duchenne-Muskeldystrophie (DMD) bekannt.
Für AGAMREE zur Behandlung von Duchen... |
| 07.10.2024 | FDA approvals and clinical advancements propel life sciences startups forward |
Alentis Therapeutics, a clinical-stage biotech company focused on developing treatments for cancer and fibrosis, has received FDA clearance for an Investigational New Drug (IND) application for ALE.P02, a novel anti-CLDN1 ADC targeting squ... |
| 25.06.2024 | Santhera Pharmaceuticals Secures Significant Financing for Growth and Debt Repayment | Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company, has recently announced the successful securing of up to CHF 69 million in financing to drive growth, repay debt, and extend its cash runway through to the first half of 202... |
| 24.06.2024 | Santhera secures up to CHF 69 million to fund operations to break-even |
Santhera’s AGAMREE for the treatment of DMD (Duchenne muscular dystrophy) as an alternative to standard corticosteroids is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), an... |
| 18.06.2024 | Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even | Ad hoc announcement pursuant to Art. 53 LR
A conference call will be held on June 19, 2024, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release. Funding underpins the advancement of AGAMREE® (vamorolone) roll-... |
| 23.04.2024 | New report presents good figures from the Swiss biotech sector as high flyers flourish |
The overall picture of the Swiss biotech industry in the Swiss Biotech Report published today is quite positive. In addition to record revenues of CHF 7.3 billion, the industry raised more than CHF 2 billion – a remarkable 50% increase ove... |
| 02.04.2024 | A positive growth trajectory for three pharmaceutical startups | Based in Basel, Santhera has pipeline of drugs for neuromuscular and pulmonary diseases that currently lack treatment options. Their drug candidate AGAMREE® (vamorolone) is a first-in-class dissociative steroid with novel mode of action, wh... |
| 22.03.2024 | FDA Nod in Duchenne Helps Wider Swath of Patients With the Rare Muscle Disease | Duchenne muscular dystrophy has several approved drugs, including a gene therapy that provides children who have the rare, inherited muscle-wasting disease the option of a one-time treatment. But each of these therapies only treats certain ... |
| 14.03.2024 | Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States | AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older This follows the first commercial launch of AGAMREE in Germany in January 2024 ... |
| 14.03.2024 | Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States | - |
| 13.10.2023 | EU approval for Santhera's vamorolone in sight | |
| 07.08.2023 | Chiesi Group acquires Santhera’s idebenone assets | |
| 20.06.2023 | Fresh money for Santhera and Idorsia | |
| 20.06.2023 | Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties | - |
| 16.01.2023 | Listed Swiss Biotechs at full throttle | |
| 28.10.2022 | Penny stock forges ahead with an NDA for Duchenne treatment, seeking priority review | After setbacks and delays, the Swiss biotech Santhera is looking to have its treatment for Duchenne muscular dystrophy get past the FDA.
Santhera, along with ReveraGen BioPharma, announced it has completed the rolling sub... |
| 01.03.2022 | New start-up takes over gene therapy approach for a rare disease from Santhera | |
| 04.01.2022 | Santhera inks exclusive agreement with USD 20M upfront payment | |
| 20.09.2021 | Santhera Secures CHF 45 Million | |
| 20.09.2021 | Santhera Secures CHF 45 Million in Funding and Announces Preliminary First Half-Year 2021 Financial Results | (MORE TO FOLLOW) Dow Jones Newswires
September 20, 2021 01:00 ET (05:00 GMT) |
| 22.06.2021 | Press Release : Santhera's Shareholders Approve all Board Proposals at Today's Annual General Meeting | Pratteln, Switzerland, June 22, 2021 -- Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders have approved all proposals by the Board of Directors at the Annual General Meeting (AGM) held today at the Company's domicile in P... |
| 27.05.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santhera Publishes Agenda for its Annual General Meeting | Pratteln, Switzerland, May 27, 2021 -- Santhera Pharmaceuticals (SIX: SANN) announces the invitation to its Annual General Meeting (AGM), which will be held on June 22, 2021, at 10:30 hrs at the domicile of the Company. Invitation and agend... |
| 07.05.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santhera Announces First Trading Day of New Convertible Bonds on SIX Swiss Exchange | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Pratteln, Switzerland, May 7, 2021 -- Santhera Pharmaceuticals (SIX: SANN) announces that trading of its CHF 30,270,375 Senior Unsecured... |
| 04.05.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Convertible Bonds due 2024 | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Pratteln, Switzerland, May 4, 2021 -- Santhera Pharmaceuticals (SIX: SANN) announces the settlement of the exchange offer in respect of ... |
| 04.05.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Santhera Pharmaceuticals : gibt den Vollzug des Umtauschangebots und die Ausgabe einer neuen vorrangigen, ungesicherten Wandelanleihe mit Fälligkeit 2024 bekannt | Santhera Pharmaceuticals Holding AG
Hohenrainstrasse 24, 4133 Pratteln, Schweiz
Tel.: +41 61 906 89 50 | Fax: +41 61 906 89 51
www.santhera.com
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL T... |
| 03.05.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Santhera Pharmaceuticals : gibt den Vollzug des Umtauschangebots für die Wandelanleihe per 4. Mai 2021 bekannt | Santhera Pharmaceuticals Holding AG
Hohenrainstrasse 24, 4133 Pratteln, Schweiz
Tel.: +41 61 906 89 50 | Fax: +41 61 906 89 51
www.santhera.com
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL T... |
| 03.05.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santhera Announces Settlement of Convertible Bond Exchange Offer on May 4, 2021 | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Pratteln, Switzerland, May 3, 2021 -- Santhera Pharmaceuticals (SIX: SANN) announces that the Exchange Offer announced on March 25, 2021... |
| 27.04.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santhera Reports End Results on Convertible Bond Exchange Offer | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Pratteln, Switzerland, April 27, 2021 -- Santhera Pharmaceuticals (SIX: SANN) announces that an aggregate principal value of around CHF ... |
| 27.04.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santhera Reports End Results on -2- | persons within the United Kingdom falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order)) or (2) persons falling wit... |
| 20.04.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santhera Reports Interim Results -2- | its officers or directors in a Swiss court or another court outside the United States for violations of the U.S. securities laws. Finally, it may be difficult to compel the Company and its affiliates to subject themselves to a U.S. court's ... |
| 20.04.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santhera Reports Interim Results on Convertible Bond Exchange Offer | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Pratteln, Switzerland, April 20, 2021 -- Santhera Pharmaceuticals (SIX: SANN) announces that so far an aggregate principal value of arou... |
| 06.04.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santhera Commences Convertible -2- | comparable to the financial statements or financial information of United States companies. It may be difficult for you to enforce your rights and any claim you may have arising under the U.S. federal securities laws in respect of the Excha... |
| 27.08.2019 | Santhera's Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there's a lot left to prove | Months after Santhera got its hands on a second Duchenne muscular dystrophy drug, the Swiss company is getting an early look at how it improves muscle function. But serious questions remain as it takes on a field stuffed ... |
| 15.02.2018 | Santhera licenses drug from Polyphor | |
| 11.12.2015 | Grundstein für neues Spin-off am Biozentrum Basel gelegt | |
| 09.09.2015 | Market approval for Santhera’s Raxone | |
| 07.08.2015 | Santhera raises CHF 27.7 million in new capital | |
| 17.04.2015 | Nine hot start-ups, 400 visitors and Joe Jimenez | |
| 03.09.2010 | Santhera and Ipsen enter into licensing agreement for Fipamezole for the treatment of Dyskinesia in Parkinson's Disease | Santhera Pharmaceuticals (SIX: SANN) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced a license agreement for the development and commercialization of fipamezole (antagonist of the adrenergic alpha-2 receptor) for territories outside o... |
| 06.11.2008 | Santhera raises CHF 15.9 million in private placement with strategic investor Ares Life Sciences | Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that it has raised gross proceeds of CHF 15.9 million in a private placement with Ares Life Sciences, an inves... |
| 05.10.2006 | Santhera raises up to EUR 15 million in oversubscribed Series C financing | Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today that it has successfully raised EUR 10 million with an option to call another EUR 5 million (in total CHF 24 million)... |
